High APRIL expression correlates with unfavourable survival of gastrointestinal stromal tumour

Pathology

Volumn 46, Issue 7, 2014, Pages 617-622

  Xian, Hua ^a   Zhang, Huilin ^b   Zhu, Huijun ^a   Wang, Xudong ^a   Tang, Xiaojun ^c   Mao, Yuan ^d   Zhu, Jin ^c,e  

^a NANTONG UNIVERSITY   (China)

^b WOMEN S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d Jiangsu Provincial Hospital   (China)

^e Huadong Medical Institute of Biotechniques   (China)

Author keywords

APRIL; GIST; Immunohistochemistry; Prognosis

Indexed keywords

DNA BINDING PROTEIN; DRUG ANALYSIS; PDS5B PROTEIN, HUMAN; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; DIAGNOSIS; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS; DIAGNOSIS; DNA-BINDING PROTEINS; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84964224955     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000162     Document Type: Article

References (38)

1. Zhu H, Lu J, Wang X, et al. Upregulated ZO-1 correlates with favorable survival of gastrointestinal stromal tumor. Med Oncol 2013; 30: 631.
2. Hemmings C, Yip D. The changing face of GIST: implications for pathologists. Pathology 2014; 46: 141-8.
3. Lee EJ, Kang G, Kang SW, et al. GSTT1 copy number gain and ZNF overexpression are predictors of poor response to imatinib in gastrointestinal stromal tumors. PLoS One 2013; 8: e77219.
4. Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 2008; 3: 557-86.
5. Tryggvason G, Gíslason HG, Magnússon MK, Jónasson JG. Gastrointestinal stromal tumors in iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005; 117: 289-93.
6. Datar M, Khanna R. Inpatient burden of gastrointestinal stromal tumors in the United States. J Gastrointest Oncol 2012; 3: 335-41.
7. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: Origin and molecular oncology. Nat Rev Cancer 2011; 11: 865-78.
8. Roggin KK, Posner MC. Modern treatment of gastric gastrointestinal stromal tumors. World J Gastroenterol 2012; 18: 6720-8.
9. Dematteo RP, Gold JS, Saran L, et al. Tumormitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008; 112: 608-15.
10. DE Vogelaere K, Van DE Winkel N, Simoens C, Delvaux G. Intragastric SILS for GIST, a new challenge in oncologic surgery: first experiences. Anticancer Res 2013; 33: 3359-63.
11. Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg 2006; 244: 176-84.
12. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620-5.
13. Schramm N, Englhart E, Schlemmer M, et al. Tumor response and clinical outcome in metastatic gastrointestinal stromal tumors under sunitinib therapy: Comparison of RECIST, Choi and volumetric criteria. Eur J Radiol 2013; 82: 951-8.
14. Bojarska-Junak A, Hus I, Chocholska S, et al. BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: Correlation with biological and clinical features. Leuk Res 2009; 33: 1319-27.
15. Wang J, Ding W, Sun B, et al. Targeting of colorectal cancer growth, metastasis, and anti-apoptosis in BALB/c nude mice via APRIL siRNA. Mol Cell Biochem 2012; 363: 1-10.
16. Sun B, Wang H, Wang X, et al. A proliferation-inducing ligand: a new biomarker for non-small cell lung cancer. Exp Lung Res 2009; 35: 486-500.
17. Hatzoglou A, Roussel J, Bourgeade MF, et al. TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J Immunol 2000; 165: 1322-30.
18. Kimchi ET, Posner MC, Park JO, et al. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res 2005; 65: 3146-54.
19. Blaveri E, Simko JP, Korkola JE, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005; 11: 4044-55.
20. Rosenwald A, Wright G, Chan WC, et al. Lymphoma/Leukemia Molecular Profiling Project: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-47.
21. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23: 70-83.
22. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006; 130: 1466-78.
23. Mao Y, Zhang DW, Zhu H, et al. LMP1 and LMP2A are potential prognostic markers of extranodal NK/T-cell lymphoma, nasal type (ENKTL). Diagn Pathol 2012; 7: 178.
24. Chen R, Lu M, Wang J, et al. Increased expression of Trop2 correlates with poor survival in extranodal NK/T cell lymphoma, nasal type. Virchows Arch 2013; 463: 713-9.
25. Fu M, FanW, Pu X, et al. Elevated expression of SHIP2 correlates with poor prognosis in non-small cell lung cancer. Int J Clin Exp Pathol 2013; 6: 2185-91.
26. Kumar K, Rowsell C, Law C, Ko YJ. Coexistence of gastrointestinal stromal tumour and colorectal adenocarcinoma: Two case reports. J Gastrointest Oncol 2011; 2: 50-4.
27. Strong VE, D'Amico TA, Kleinberg L, Ajani J. Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. J Natl Compr Canc Netw 2013; 11: 60-6.
28. Roth W, Wagenknecht B, Klumpp A, et al. APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis. Cell Death Differ 2001; 8: 403-10.
29. Wang F, Chen L, Mao ZB, Shao JG, Tan C, Huang WD. Lentivirusmediated short hairpin RNA targeting the APRIL gene suppresses the growth of pancreatic cancer cells in vitro and in vivo. Oncol Rep 2008; 20: 135-9.
30. Moreaux J, Veyrune JL, De Vos J, Klein B. APRIL is overexpressed in cancer: link with tumor progression. BMC Cancer 2009; 9: 83.
31. Kubota D, Yoshida A, Tsuda H, et al. Gene expression network analysis of ETV1 reveals KCTD10 as a novel prognostic biomarker in gastrointestinal stromal tumor. PLoS One 2013; 8: e73896.
32. Mhawech-Fauceglia P, Allal A, Odunsi K, Herrmann FR, Huard B. Role of the tumour necrosis family ligand APRIL in solid tumour development: Retrospective studies in bladder, ovarian and head and neck carcinomas. Eur J Cancer 2008; 44: 2097-100.
33. Petty RD, Samuel LM, Murray GI, et al. APRIL is a novel clinical chemoresistance biomarker in colorectal adenocarcinoma identified by gene expression profiling. BMC Cancer 2009; 9: 434.
34. Agaimy A. Risk assessment and pathological reporting of gastrointestinal stromal tumour. Diagn Histopathol 2013; 19: 191-7.
35. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39: 1411-9.
36. Joensuu H, Vehtari A, Riihima?ki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled populationbased cohorts. Lancet Oncol 2012; 13: 265-74.
37. Díaz-Delgado M, Hernández-Amate A, Sánchez-León M, et al. Multiple non-metastatic gastrointestinal stromal tumors. Differential features. Rev Esp Enferm Dig 2010; 102: 489-97.
38. Pandurengan RK, Dumont AG, Araujo DM, et al. Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol 2010; 21: 2107-11.